Applied DNA Sciences Inc (APDN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Applied DNA Sciences Inc (APDN) has a cash flow conversion efficiency ratio of -0.403x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.82 Million) by net assets ($6.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See APDN equity financing ratio to measure how much of total assets are equity-financed.
Applied DNA Sciences Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Applied DNA Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Applied DNA Sciences Inc (APDN) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Applied DNA Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied DNA Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Golden Metal Resources PLC
LSE:GMET
|
-0.027x |
|
CGN Resources Ltd
AU:CGR
|
-0.393x |
|
Ashtead Technology Holdings PLC
LSE:AT
|
0.153x |
|
Harfang Exploration Inc
V:HAR
|
-0.017x |
|
New Plus Knitting Public Company Limited
BK:NPK
|
-0.003x |
|
M3 Mining Ltd
AU:M3M
|
-0.538x |
|
C&C Group plc
LSE:CCR
|
0.072x |
|
Prima Alloy Steel Universal
JK:PRAS
|
0.006x |
Annual Cash Flow Conversion Efficiency for Applied DNA Sciences Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Applied DNA Sciences Inc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see Applied DNA Sciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.94 Million | $-12.24 Million | -6.305x | -312.39% |
| 2024-09-30 | $8.97 Million | $-13.71 Million | -1.529x | -19.81% |
| 2023-09-30 | $4.87 Million | $-6.22 Million | -1.276x | -83.51% |
| 2022-09-30 | $12.91 Million | $-8.98 Million | -0.695x | +42.28% |
| 2021-09-30 | $11.11 Million | $-13.39 Million | -1.205x | +38.27% |
| 2020-09-30 | $5.71 Million | $-11.14 Million | -1.952x | -124.13% |
| 2019-09-30 | $-848.50K | $-6.86 Million | 8.087x | +188.21% |
| 2018-09-30 | $754.50K | $-6.92 Million | -9.168x | -740.66% |
| 2017-09-30 | $6.86 Million | $-7.48 Million | -1.091x | -14.22% |
| 2016-09-30 | $10.37 Million | $-9.90 Million | -0.955x | -72.25% |
| 2015-09-30 | $12.57 Million | $-6.97 Million | -0.554x | -109.56% |
| 2014-09-30 | $-1.47 Million | $-8.51 Million | 5.797x | +440.00% |
| 2013-09-30 | $4.62 Million | $-7.87 Million | -1.705x | +67.42% |
| 2012-09-30 | $756.92K | $-3.96 Million | -5.233x | -238.46% |
| 2011-09-30 | $-995.38K | $-3.76 Million | 3.779x | +145.98% |
| 2010-09-30 | $-1.60 Million | $-2.46 Million | 1.536x | +8.72% |
| 2009-09-30 | $-1.75 Million | $-2.47 Million | 1.413x | +577.91% |
| 2008-09-30 | $-14.04 Million | $-2.93 Million | 0.208x | +10.59% |
| 2007-09-30 | $-11.94 Million | $-2.25 Million | 0.189x | -37.34% |
| 2006-09-30 | $-9.59 Million | $-2.88 Million | 0.301x | +121.74% |
| 2005-09-30 | $6.59 Million | $-9.12 Million | -1.384x | -312.27% |
| 2004-09-30 | $-4.71 Million | $-3.07 Million | 0.652x | -23.40% |
| 2003-09-30 | $-577.43K | $-491.51K | 0.851x | -92.86% |
| 2001-09-30 | $-828.00 | $-9.87K | 11.914x | -- |
About Applied DNA Sciences Inc
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops… Read more